Vandria Reports Positive Phase I Results for Alzheimer’s Drug VNA-318

Vandria has announced promising Phase I results for VNA-318, an orally bioavailable, brain-penetrant small molecule being developed for Alzheimer’s disease. The first-in-human trial, involving 92 healthy men, reported no severe or serious adverse events and no discontinuations, confirming a favorable safety and tolerability profile.

VNA-318 has a dual mechanism of action and targets cognitive decline and functional loss. Pre-clinical studies showed rapid cognitive improvements, reduced toxic protein aggregation, lower neuroinflammation, and enhanced mitochondrial function. The compound’s target is genetically linked to several human diseases, including Alzheimer’s.

The randomized, double-blind single and multiple ascending dose study demonstrated low pharmacokinetic variability, a long half-life, and dose-linear exposure, supporting once-daily dosing. A significant dose-dependent change in a key biomarker further supports Phase II advancement.

Vandria plans a Series B round in 2026 to fund Phase II proof-of-concept trials and support its growing pre-clinical pipeline in liver, muscle, and lung diseases.

08-12-2025